Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Symptomatic case 7% primary Improvement Relative Risk Case -108% post-hoc primary c19melatonin.com García-García et al. Melatonin for COVID-19 RCT Prophylaxis Favors melatonin Favors control
García-García, 314 patient melatonin prophylaxis RCT: 108% more cases [p=0.26] https://c19p.org/garciagarcia
copied to clipboard
Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial
García-García et al., Journal of Clinical Medicine, doi:10.3390/jcm11041139
21 Feb 2022    Source   PDF   Share   Tweet
PrEP RCT healthcare workers in Spain, showing no significant difference in cases with melatonin prophylaxis. Most cases were asymptomatic or paucisymtomatic, there were two symptomatic cases, no moderate/severe cases, and no hospitalization.
The registered primary outcome is symptomatic cases. Authors report on all cases due to the small number of symptomatic cases. They did not include the original primary outcome results in the paper, but have provided the results via email to a contributor.
The dosage in this trial is very low, 2mg daily. Meta regression suggests higher doses are much more effective.
MeCOVID. EudraCT 2020-001530-35. NCT04353128 (history).
risk of symptomatic case, 7.4% lower, RR 0.93, p = 1.00, treatment 1 of 163 (0.6%), control 1 of 151 (0.7%), NNT 2051, primary outcome.
risk of case, 108.4% higher, RR 2.08, p = 0.26, treatment 9 of 163 (5.5%), control 4 of 151 (2.6%), post-hoc primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
García-García et al., 21 Feb 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, peer-reviewed, 25 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMelatoninAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit